Results 201 to 210 of about 77,790 (265)

Pediatric Trauma Trends Before and After Recreational Cannabis Legalization in Nevada: A Retrospective Repeated Cross-Sectional Study. [PDF]

Children (Basel)
Serr J, Goel V, Sagaribay R, Batra K, Shah AP.   +4 more
europepmc   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Cannabis Intoxication Does Not Impact Nutritional Status in Patients With Small Burns. [PDF]

J Burn Care Res
Wang S, Stanton E, Emeh A, Manasyan A, Wong S, Boudiab E, Baranco P, Johnson MB, Gillenwater TJ.   +8 more
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade, Nathan Morris, Diana E. Sepulveda, Alonso Cortez‐Resendiz, Christopher Brandl, Jennifer E. Lausch, Mariya Starostina, Nicholas M. Graziane   +7 more
wiley   +1 more source

The Short-Term Change in Knowledge of Cannabis-Related Risks After a Brief Curriculum-Integrated School Intervention Among Adolescents: A Quasi-Experimental Pre-Post Study. [PDF]

Healthcare (Basel)
Azón-Belarre JC, Berges-Usán P, Gómez-Torres P, Romeo-García J, García-Guerra MT, Membrive-Jiménez MJ, Galarreta-Aperte S.   +6 more
europepmc   +1 more source

5‐HT2A receptor agonism by tert‐leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli, Deborah Rudin, Dino Luethi, Matthias E. Liechti, Sabrine Bilel, Matteo Marti, Henrik Green, Manuela Carla Monti, Caitlyn Norman   +8 more
wiley   +1 more source

Chronic cannabis use and sleep architecture: a cross-sectional analysis of polysomnography outcomes in a sleep-clinic cohort. [PDF]

Sleep
Velzeboer R, Wei S, Lai WWK.
europepmc   +1 more source

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults. [PDF]

Am J Prev Med
Yang KH, Satybaldiyeva N, Kepner W, Friedman J, Ping S, Leas EC.   +5 more
europepmc   +1 more source